Omics-Driven Immune Challenge Design: What Early Human Data Tells Us

A cytokine shift or a change in skin perfusion can confirm that an immune response occurred, yet say little about which pathways, cells, or compartments drove it.

Part of a series on early human data, this article looks at how systems-level profiling sharpens the choice and interpretation of a challenge model. It draws on three CHDR studies in healthy participants, covering intravenous LPS, topical imiquimod, and KLH recall challenge. Blood and bone marrow turned out to behave differently, and visible skin endpoints plateaued while tissue biology kept changing. The authors are equally direct about limits: small samples, bulk sequencing constraints, and the gap between a challenge model and a disease.

Discover the data and what it means for pharmacodynamic endpoint selection.